| Literature DB >> 30563515 |
Hongyun Liu1,2, Ping Zhan2, Jinlong Shi1,2, Guojing Wang1,2, Buqing Wang1, Weidong Wang3,4.
Abstract
BACKGROUND: Phase-rectified signal averaging (PRSA) was often applied to assess the cardiac vagal modulation. Despite its broad use, this method suffers from the confounding effects of anomalous variants of sinus rhythm. This study aimed to improve the original PRSA method in deceleration capacity (DC) quantification.Entities:
Keywords: Autonomic nervous system; Deceleration capacity; Heart rate variability; Phase-rectified signal averaging
Mesh:
Year: 2018 PMID: 30563515 PMCID: PMC6299532 DOI: 10.1186/s12938-018-0618-x
Source DB: PubMed Journal: Biomed Eng Online ISSN: 1475-925X Impact factor: 2.819
Fig. 1Illustration of anchor points selection. a Anchor points for a real ECG recording. Deceleration-related anchor points selected from heartbeat interval time series according to original PRSA (b) and modified PRSA (c) method, respectively
Demographic data and clinical factors of all study population
| Variables | Healthy (n = 191) | ESRD (n = 51) |
|---|---|---|
| Male/female | 96/95 | 30/21 |
| Age (year) | 38.0 ± 15.5 | 60.0 ± 11.9 |
| Height (cm) | 168.8 ± 10.4 | NA |
| Weight (kg) | 69.6 ± 15.2 | NA |
| BMI (kg/cm2) | 20.07 ± 4.44 | NA |
| BP_SYS (mmHg) | 116 ± 13 | 139 ± 22 |
| BP_DIA (mmHg) | 75 ± 8 | 76 ± 13 |
| Diabetes Mellitus, n (%) | NA | 32 (62.7%) |
| Hypertension, n (%) | NA | 48 (94.1%) |
| LVEF (%) | NA | 59 ± 16 |
| Glucose (mg/dL) | NA | 121 ± 49 |
| Calcium (mg/dL) | NA | 8.9 ± 1.6 |
| Phosphate (mg/dL) | NA | 5.2 ± 1.4 |
| Albumin (g/dL) | NA | 4.0 ± 0.4 |
| Hemoglobin (g/dL) | NA | 13.1 ± 12.3 |
| Creatinine (mg/dL) | NA | 8.6 ± 2.8 |
NA not available, BMI body mass index, BP_SYS systolic blood pressure, BP_DIA diastolic blood pressure, LVEF left ventricular ejection fraction, ESRD end-stage renal disease
Fig. 2Representative original and refined PRSA signals of 24-h (a, b), 2-h (c, d) and 30-min (e, f) recordings of heartbeat intervals in one patient with end-stage renal disease (ESRD)
Fig. 3The averages of the normalized spectra obtained with the original and refined PRSA signal in the end-stage renal disease (ESRD) group for 24-h (a), 2-h (b), and 30-min (c) recordings of heartbeat intervals
Measures of original and refined deceleration capacity in healthy and ESRD groups
| Variables | Healthy (n = 191) | ESRD (n = 51) | p value | AUC | Youden’s index |
|---|---|---|---|---|---|
| 24-h | |||||
| | 13.43 ± 5.60 | 4.36 ± 2.60 | < 0.001 | 0.945 ± 0.017 | 0.766 |
| | 17.77 ± 6.79 | 6.25 ± 3.59 | < 0.001 | 0.944 ± 0.018 | 0.774 |
| 2-h | |||||
| | 11.94 ± 5.28 | 3.50 ± 1.87 | < 0.001 | 0.960 ± 0.013 | 0.802 |
| | 16.61 ± 6.94 | 4.81 ± 2.39 | < 0.001 | 0.969 ± 0.011 | 0.842 |
| 30-min | |||||
| | 12.40 ± 5.46 | 3.25 ± 1.94 | < 0.001 | 0.967 ± 0.012 | 0.825 |
| | 17.14 ± 7.12 | 4.53 ± 2.60 | < 0.001 | 0.971 ± 0.011 | 0.830 |
DC original deceleration capacity, DC refined deceleration capacity, ESRD end-stage renal disease, AUC area under receiver operating characteristic curve
Fig. 4Analysis of the discrimination power of the healthy and end-stage renal disease (ESRD) groups by receiver operating characteristic curve (ROC) analysis. The areas under the curve (AUC) of DC and DC were 0.945 vs. 0.944, 0.960 vs. 0.969, and 0.967 vs. 0.971 for a 24-h, b 2-h and c 30-min ECG recordings, respectively